512 related articles for article (PubMed ID: 23034282)
41. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
42. Caffeic acid phenethyl ester (CAPE) revisited: Covalent modulation of XPO1/CRM1 activities and implication for its mechanism of action.
Wu S; Zhang K; Qin H; Niu M; Zhao W; Ye M; Zou H; Yang Y
Chem Biol Drug Des; 2017 May; 89(5):655-662. PubMed ID: 27863053
[TBL] [Abstract][Full Text] [Related]
43. Atomic basis of CRM1-cargo recognition, release and inhibition.
Fung HY; Chook YM
Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
[TBL] [Abstract][Full Text] [Related]
44. Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals.
Fung HY; Fu SC; Chook YM
Elife; 2017 Mar; 6():. PubMed ID: 28282025
[TBL] [Abstract][Full Text] [Related]
45. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract][Full Text] [Related]
46. Understanding XPO1 target networks using systems biology and mathematical modeling.
Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
[TBL] [Abstract][Full Text] [Related]
47. Correlation of CRM1-NES affinity with nuclear export activity.
Fu SC; Fung HYJ; Cağatay T; Baumhardt J; Chook YM
Mol Biol Cell; 2018 Aug; 29(17):2037-2044. PubMed ID: 29927350
[TBL] [Abstract][Full Text] [Related]
48. The export receptor Crm1 forms a dimer to promote nuclear export of HIV RNA.
Booth DS; Cheng Y; Frankel AD
Elife; 2014 Dec; 3():e04121. PubMed ID: 25486595
[TBL] [Abstract][Full Text] [Related]
49. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
50. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
[TBL] [Abstract][Full Text] [Related]
51. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
[TBL] [Abstract][Full Text] [Related]
52. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
54. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
[TBL] [Abstract][Full Text] [Related]
55. Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.
Mathew C; Tamir S; Tripp RA; Ghildyal R
Sci Rep; 2021 Sep; 11(1):19223. PubMed ID: 34584169
[TBL] [Abstract][Full Text] [Related]
56. Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry.
Thakar K; Karaca S; Port SA; Urlaub H; Kehlenbach RH
Mol Cell Proteomics; 2013 Mar; 12(3):664-78. PubMed ID: 23242554
[TBL] [Abstract][Full Text] [Related]
57. Structural basis for leucine-rich nuclear export signal recognition by CRM1.
Dong X; Biswas A; Süel KE; Jackson LK; Martinez R; Gu H; Chook YM
Nature; 2009 Apr; 458(7242):1136-41. PubMed ID: 19339969
[TBL] [Abstract][Full Text] [Related]
58. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
60. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
